malignancy
Conditions
Interventions
the group of standardized pharmaceutical care -Trial group (standardized pharmaceutical care):None
Control group (without standardized pharmaceutical care):None
Sponsors
Department of Pharmacy, West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed as malignant tumors by pathology, including solid tumors and hematological tumors, with an expected survival period of >= 3 months; 2. Anti-tumor drugs with cardiovascular toxicity were included, including anthracyclines, fluorouracil, taxanes and other chemotherapy drugs, targeted drugs such as trastuzumab, osimertinib, Crizotinib, Bevacizumab, and Immune checkpoint inhibitors such as Pembrolizumab, Atezolizumab, and Nivolumab; 3. Age >= 18 years old; 4. ECOG physical condition score 0-3 points; 5. Hematology, liver and kidney function, and important organ function indicators meet the requirements for receiving anti-tumor drugs.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Merge severe and irreversible cardiovascular diseases; 3. Patients who have received chest radiation therapy in the past or during enrollment; 4. Subjects who are unable to read or independently complete the questionnaire survey; 5. Individuals with mental illness; 6. Patients who have experienced severe drug-related cardiovascular events in the past; 7. The researchers did not consider it suitable for enrollees.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardiovascular adverse events;The incidence of serious cardiovascular adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| The patients' satisfaction degree;the doctors' satisfactory degree ;Medication Compliance in patients;The proportion of doctors and nurses adopting pharmacist's opinions; | — |
Countries
China
Contacts
Public ContactHe Jinhan
West China Hospital of Sichuan University
Outcome results
None listed